A Phase 3 interventional study of Obeldesivir and Obeldesivir Placebo in COVID-19, sponsored by Gilead Sciences. Terminated at 81 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in COVID-19 by Gilead Sciences — none open to participants now, none under way, none of them phase 3. COVID-19 · Gilead Sciences.
Among the 10 studies in COVID-19 by Gilead Sciences, this one is the only one that started in 2022, is one of 6 in phase 3, and was the 8th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 10 studies in COVID-19 by Gilead Sciences is open now. The open studies under COVID-19, anywhere →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 8
First in 2020; this study’s year is marked. 1 started in 2022.
This study's enrollment of 468 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 468 across the 9 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in COVID-19 by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to test how well the study drug, obeldesivir (GS-5245), works and how safe it is in treating coronavirus disease 2019 (COVID-19) in participants that have a higher risk of getting a serious illness.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive obeldesivir 350 mg orally twice daily for 5 days.
Drug: Obeldesivir
Participants will receive placebo-to-match obeldesivir orally twice daily for 5 days.
Drug: Obeldesivir Placebo
Tablets administered orally without regard to food.
Also known as: GS-5245
Placebo tablets administered orally without regard to food.
Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization or All-Cause Death by Day 29
COVID-19-related hospitalization was defined as ≥ 24 hours of acute care for a reason related to COVID-19, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This included specialized acute medical care units within an assisted living facility or nursing home. This did not include hospitalization for the purposes of public health and/or clinical trial execution. The date and duration of hospital admission, and primary reason for hospitalization (including if the hospitalization was related to COVID-19) were recorded. Percentages were rounded off.
Time frame: Up to Day 29
Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)
TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. Any AEs leading to premature discontinuation of study drug. Percentages were rounded off.
Time frame: First dose date up to 5 Days plus 30 Days
Percentage of Participants Experiencing Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Percentages were rounded off.
Time frame: First dose date up to 5 Days plus 30 Days
Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation
A treatment emergent AE is defined as an AE that occurs or worsens in severity on or after the date of the first dose of study drug but no later than 30 days after the permanent discontinuation of study drug or an AE leading to discontinuation of study drug. A SAE is defined as an event that, at any dose, resulted in any of the following: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. Percentages were rounded off.
Time frame: First dose date up to 5 Days plus 30 Days
Percentage of Participants With All-Cause Hospitalization by Day 29
All-cause hospitalization was defined as ≥ 24 hours of acute care, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This includes specialized acute medical care units within an assisted living facility or nursing home. This does not include hospitalization for the purposes of public health and/or clinical study execution. The date and duration of hospital admission, and primary reason for hospitalization (including if the hospitalization is related to COVID-19) were recorded. Percentages were rounded off.
Time frame: Up to Day 29
Percentage of Participants With COVID-19-Related Medically Attended Visits (MAVs) or All-Cause Death by Day 29
Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.
Time frame: Up to Day 29
Percentage of Participants With COVID-19-Related MAVs by Day 29
Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.
Time frame: Up to Day 29
Percentage of Participants With All-cause Death by Day 29
Percentages were rounded off.
Time frame: Up to Day 29
Time to COVID-19 Symptom Alleviation by Day 15
Time to COVID-19 symptom alleviation was calculated as symptom alleviation date/time minus the first dose date/time. Symptom alleviation was evaluated for the 15 targeted symptoms using symptoms of infection with coronavirus-19 (SIC) questionnaire. The SIC questionnaire assessed all targeted symptoms, alleviation was defined as the SIC rating of 0, or at least 3 points decrease in rating from baseline, or an answer "No" to the question for at least 48 consecutive hours.
Time frame: Up to Day 15
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5
The mixed model for repeated measures (MMRM) was used for analysis.
Time frame: Day 5
Plasma Concentrations of GS-441524 (Metabolite of Obeldesivir)
Time frame: Day 1, 0.75 and 2 hours postdose and Day 5 predose and 0.75 hours postdose
Participants were enrolled at study sites in the South America, Europe, North America, Africa and Asia.
| Milestone | Obeldesivir | Placebo |
|---|---|---|
| Started | 233 | 235 |
| Completed | 224 | 227 |
| Not completed | 9 | 8 |
| Withdrew: Withdrew consent | 6 | 2 |
| Withdrew: Randomized but never treated | 0 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Investigator's discretion | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
COVID-19-related hospitalization was defined as ≥ 24 hours of acute care for a reason related to COVID-19, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This included specialized acute medical care units within an assisted living facility or nursing home. This did not include hospitalization for the purposes of public health and/or clinical trial execution. The date and duration of hospital admission, and primary reason for hospitalization (including if the hospitalization was related to COVID-19) were recorded. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization or All-Cause Death by Day 29 | 0 | 0.5 |
TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. Any AEs leading to premature discontinuation of study drug. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) | 22.2 | 20.8 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Any grade | 56.1 | 61.7 |
| Grade 3 or 4 | 6.5 | 4.8 |
A treatment emergent AE is defined as an AE that occurs or worsens in severity on or after the date of the first dose of study drug but no later than 30 days after the permanent discontinuation of study drug or an AE leading to discontinuation of study drug. A SAE is defined as an event that, at any dose, resulted in any of the following: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| AEs Leading to Study Drug Discontinuation | 1.7 | 0.9 |
| SAEs Leading to Study Drug Discontinuation | 0.9 | 0.9 |
All-cause hospitalization was defined as ≥ 24 hours of acute care, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This includes specialized acute medical care units within an assisted living facility or nursing home. This does not include hospitalization for the purposes of public health and/or clinical study execution. The date and duration of hospital admission, and primary reason for hospitalization (including if the hospitalization is related to COVID-19) were recorded. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With All-Cause Hospitalization by Day 29 | 0.5 | 0 |
Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With COVID-19-Related Medically Attended Visits (MAVs) or All-Cause Death by Day 29 | 1.0 | 1.0 |
Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With COVID-19-Related MAVs by Day 29 | 1 | 0.5 |
Percentages were rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants With All-cause Death by Day 29 | 0 | 0.5 |
Time to COVID-19 symptom alleviation was calculated as symptom alleviation date/time minus the first dose date/time. Symptom alleviation was evaluated for the 15 targeted symptoms using symptoms of infection with coronavirus-19 (SIC) questionnaire. The SIC questionnaire assessed all targeted symptoms, alleviation was defined as the SIC rating of 0, or at least 3 points decrease in rating from baseline, or an answer "No" to the question for at least 48 consecutive hours.
| Days | Obeldesivir | Placebo |
|---|---|---|
| Time to COVID-19 Symptom Alleviation by Day 15 | 7.3 (5.4 to 9.4) | 9.3 (6.5 to NA) |
The mixed model for repeated measures (MMRM) was used for analysis.
| log10 copies/mL | Obeldesivir | Placebo |
|---|---|---|
| Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5 | -2.80 ± 0.092 | -2.22 ± 0.092 |
| ng/mL | Obeldesivir |
|---|---|
| Day 1, 0.75 hours postdose | 2330.42 ± 1709.560 |
| Day 1, 2 hours postdose | 2535.84 ± 1370.131 |
| Day 5, Predose | 1116.81 ± 1101.371 |
| Day 5, 0.75 hours postdose | 3089.09 ± 1839.992 |
Collected over All-cause mortality, Adverse events: First dose date up to 5 Days plus 30 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obeldesivir | 0/234 (0%) | 2/234 (0.9%) | 0/234 (0%) |
| Placebo | 1/234 (0.4%) | 2/231 (0.9%) | 0/231 (0%) |
| Event | Obeldesivir | Placebo |
|---|---|---|
| VomitingGastrointestinal disorders | 0/234 | 1/231 |
| DeathGeneral disorders | 0/234 | 1/231 |
| DizzinessNervous system disorders | 1/234 | 0/231 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/234 | 0/231 |
The All Randomized Analysis Set included all participants who were randomized in the study.
| Age, Continuous(years) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Mean | 57 ± 14.9 | 53 ± 16.6 | 55 ± 15.8 |
| Age, Customized(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Adults (18 - 64 Years) | 159 | 173 | 332 |
| Geriatrics (65 - 84 Years) | 71 | 59 | 130 |
| Geriatrics (85 Years and Over) | 3 | 3 | 6 |
| Sex: Female, Male(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Female | 147 | 117 | 264 |
| Male | 86 | 118 | 204 |
| Ethnicity (NIH/OMB)(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 36 | 43 | 79 |
| Not Hispanic or Latino | 197 | 192 | 389 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| White | 178 | 168 | 346 |
| Asian | 24 | 32 | 56 |
| American Indian or Alaska Native | 21 | 19 | 40 |
| Black or African American | 9 | 10 | 19 |
| Other or More Than One Race | 1 | 4 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Romania | 29 | 24 | 53 |
| Singapore | 1 | 0 | 1 |
| Hungary | 0 | 1 | 1 |
| Japan | 2 | 3 | 5 |
| United Kingdom | 8 | 0 | 8 |
| Portugal | 4 | 5 | 9 |
| Spain | 11 | 12 | 23 |
| Canada | 7 | 11 | 18 |
| South Korea | 1 | 2 | 3 |
| Turkey | 1 | 1 | 2 |
| Taiwan | 17 | 23 | 40 |
| Brazil | 3 | 5 | 8 |
| Poland | 12 | 7 | 19 |
| Italy | 1 | 1 | 2 |
| Mexico | 24 | 24 | 48 |
| South Africa | 15 | 16 | 31 |
| Bulgaria | 97 | 99 | 196 |
| France | 0 | 1 | 1 |
| Baseline Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load(log10 copies/mL) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Mean | 6.15 ± 1.629 | 6.15 ± 1.622 | 6.15 ± 1.624 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2022 to primary completion in Nov 2023, 12 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obeldesivir